Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther 2010 Jun;9(6):1485-8
Date
05/27/2010Pubmed ID
20501803Pubmed Central ID
PMC3108331DOI
10.1158/1535-7163.MCT-10-0156Scopus ID
2-s2.0-77953441380 (requires institutional sign-in at Scopus site) 60 CitationsAbstract
Castleman's disease (CD) is a very rare lymphoproliferative disorder whose underlying pathophysiology is not fully understood and for which no standard treatment exists. Because interleukin-1 (IL-1) might promote the production of interleukin-6 (IL-6), a key pathogenic factor for the disease, we hypothesized that blocking the interleukin-1 receptor would be a useful therapy for CD. We report the case of a 61-year-old woman with CD who had undergone multiple treatments, including cladribine, rituximab, steroids, etanercept, and anti-IL-6 monoclonal antibody, and whose disease was refractory to all of these treatments. She was started on the recombinant IL-1 receptor antagonist, Anakinra, at a subcutaneous dose of 100 mg daily. Within one week, her fatigue and anorexia markedly improved, and her laboratory abnormalities, including anemia, thrombocytosis, leukocytosis, and elevated markers of inflammation, all resolved. Our observation suggests that Anakinra may be an attractive therapeutic approach for refractory multicentric CD.
Author List
El-Osta H, Janku F, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Blood Cell CountCastleman Disease
Female
Fluorodeoxyglucose F18
Humans
Interleukin 1 Receptor Antagonist Protein
Middle Aged
Positron-Emission Tomography
Whole Body Imaging